IRCT20210531051453N1.

Study name	Public title: Effect of omega‐3 fatty acid in borderline personality disorder Scientific title: Study the effectiveness of omega‐3 fatty acids as adjuvant treatment on depression, aggression and poor impulse control in hospitalized patients of borderline personality disorder
Methods	Allocation: randomised Intervention model: parallel assignment Blinding: double‐blinded Duration: 6 weeks Timing of assessment: at baseline and 12 weeks after the trial
Participants	Inclusion criteria Definitive diagnosis of Borderline Personality Disorder based on DSM‐V Aged 18‐60 Disorder leading to referral for treatment and hospitalisation IQ > 70 Patient and patients have conscious consent to participant in the study. Exclusion criteria Having any psychological disorders (except substance abuse disorder) Having diabetes, metabolic disorders, serious medical or neurological diseases Having extrapyramidal symptoms such as hands tremor, mouthwatering, neck dystonia, rigidity, and akathisia Pregnancy and/or breastfeeding
Interventions	Experimental Drug name: omega‐3 Brand name: Actover Pharmaceutical Company Drug dose: 2 grams per day Route of administration: oral Administration: daily for 6 weeks Comparator Drug name: olanzapine Brand name: Abidi Pharmaceutical Company Drug dose: 5‐15 mg per day, according to patent’s response Route of administration: oral Administration: daily for 6 weeks
Outcomes	Primary outcome Depression, using the Hamilton scale  Secondary outcomes Aggression, using the Bus and Perry scale  Impulse control, using an impulse control measurement based on the Barrat scale
Starting date	8 January 2020
Contact information	Name: Ensieh Sadri Address: No 17, South Ebrahimi Ave, East Ferdos Blvd, Tehran 1481958465 Tehran Iran (Islamic Republic of) Phone: +98 21 4405 7355 Email: sadri.ensieh@gmail.com
Notes	Source of funding: University of Social Welfare and Rehabilitation Sciences